Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 10 | 2021 | 1535 | 1.560 |
Why?
|
| Blood Pressure | 9 | 2019 | 1451 | 1.500 |
Why?
|
| Antihypertensive Agents | 5 | 2019 | 498 | 1.060 |
Why?
|
| Anemia, Sickle Cell | 4 | 2014 | 364 | 0.740 |
Why?
|
| Child | 29 | 2021 | 6405 | 0.730 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2016 | 161 | 0.680 |
Why?
|
| Nephrotic Syndrome | 7 | 2017 | 61 | 0.610 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2014 | 89 | 0.540 |
Why?
|
| Adolescent | 24 | 2019 | 8912 | 0.530 |
Why?
|
| Kidney Transplantation | 6 | 2015 | 839 | 0.520 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 122 | 0.520 |
Why?
|
| Obesity | 3 | 2012 | 1076 | 0.490 |
Why?
|
| Immunosuppressive Agents | 5 | 2015 | 514 | 0.490 |
Why?
|
| Hydralazine | 1 | 2014 | 12 | 0.470 |
Why?
|
| Prehypertension | 1 | 2013 | 40 | 0.430 |
Why?
|
| Masked Hypertension | 1 | 2012 | 7 | 0.420 |
Why?
|
| Blood Pressure Determination | 1 | 2013 | 152 | 0.420 |
Why?
|
| Uric Acid | 1 | 2012 | 37 | 0.410 |
Why?
|
| Albuminuria | 2 | 2010 | 171 | 0.410 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2012 | 43 | 0.400 |
Why?
|
| Aldosterone | 1 | 2011 | 51 | 0.380 |
Why?
|
| Renin-Angiotensin System | 2 | 2015 | 79 | 0.380 |
Why?
|
| Renin | 1 | 2011 | 96 | 0.370 |
Why?
|
| Graft Survival | 1 | 2012 | 465 | 0.340 |
Why?
|
| Adiponectin | 1 | 2009 | 52 | 0.330 |
Why?
|
| Nutrition Surveys | 3 | 2014 | 208 | 0.300 |
Why?
|
| Male | 26 | 2021 | 37321 | 0.290 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 56 | 0.280 |
Why?
|
| Humans | 33 | 2021 | 68618 | 0.280 |
Why?
|
| Prednisone | 1 | 2007 | 104 | 0.280 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 202 | 0.280 |
Why?
|
| Cyclosporine | 1 | 2007 | 121 | 0.270 |
Why?
|
| Female | 25 | 2021 | 38074 | 0.270 |
Why?
|
| Retrospective Studies | 11 | 2015 | 7277 | 0.250 |
Why?
|
| Glucocorticoids | 1 | 2007 | 222 | 0.250 |
Why?
|
| Child, Preschool | 10 | 2015 | 3187 | 0.250 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 940 | 0.240 |
Why?
|
| Body Mass Index | 3 | 2013 | 867 | 0.240 |
Why?
|
| Disease Progression | 3 | 2016 | 1038 | 0.210 |
Why?
|
| Biomarkers | 5 | 2015 | 1593 | 0.210 |
Why?
|
| Heart Rate | 2 | 2014 | 568 | 0.200 |
Why?
|
| Bifidobacterium | 1 | 2021 | 1 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2015 | 2358 | 0.180 |
Why?
|
| Risk Factors | 8 | 2015 | 5731 | 0.180 |
Why?
|
| Prevalence | 4 | 2014 | 1619 | 0.180 |
Why?
|
| Logistic Models | 3 | 2015 | 1420 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 155 | 0.160 |
Why?
|
| Nephrology | 2 | 2015 | 43 | 0.150 |
Why?
|
| Renal Dialysis | 2 | 2016 | 174 | 0.150 |
Why?
|
| Quality of Life | 2 | 2017 | 1515 | 0.150 |
Why?
|
| Proteinuria | 3 | 2015 | 136 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 529 | 0.140 |
Why?
|
| Dietary Supplements | 2 | 2016 | 332 | 0.140 |
Why?
|
| Indican | 1 | 2016 | 1 | 0.140 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2016 | 17 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 114 | 0.140 |
Why?
|
| Steroids | 2 | 2007 | 84 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 1046 | 0.130 |
Why?
|
| Oxides | 1 | 2016 | 47 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 33 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.130 |
Why?
|
| Self Report | 1 | 2017 | 371 | 0.130 |
Why?
|
| Nephritis | 1 | 2015 | 37 | 0.130 |
Why?
|
| Indoles | 1 | 2016 | 146 | 0.130 |
Why?
|
| Carbon | 1 | 2016 | 122 | 0.130 |
Why?
|
| Social Skills | 1 | 2015 | 14 | 0.130 |
Why?
|
| Age Distribution | 2 | 2014 | 320 | 0.120 |
Why?
|
| Fetus | 1 | 2015 | 157 | 0.120 |
Why?
|
| Maternal Exposure | 1 | 2015 | 75 | 0.120 |
Why?
|
| Graft Rejection | 3 | 2015 | 458 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.120 |
Why?
|
| Linear Models | 2 | 2015 | 521 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 121 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2015 | 7029 | 0.120 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 215 | 0.110 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 172 | 0.110 |
Why?
|
| Age Factors | 3 | 2014 | 1864 | 0.110 |
Why?
|
| Young Adult | 4 | 2015 | 5717 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 292 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 33 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2012 | 35 | 0.100 |
Why?
|
| United States | 3 | 2015 | 7367 | 0.100 |
Why?
|
| Vincristine | 1 | 2012 | 44 | 0.100 |
Why?
|
| Fluconazole | 1 | 2012 | 26 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 296 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 212 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2012 | 87 | 0.100 |
Why?
|
| Biopsy | 4 | 2015 | 540 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 335 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 88 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 70 | 0.100 |
Why?
|
| Hospitalization | 2 | 2015 | 978 | 0.100 |
Why?
|
| Midwestern United States | 3 | 2015 | 36 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2012 | 112 | 0.100 |
Why?
|
| Sex Factors | 2 | 2012 | 1266 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2012 | 108 | 0.100 |
Why?
|
| Reference Values | 1 | 2012 | 579 | 0.100 |
Why?
|
| Vitamin D | 1 | 2015 | 516 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 1085 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 536 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2012 | 365 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 504 | 0.090 |
Why?
|
| Kidney | 1 | 2015 | 945 | 0.090 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 62 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 792 | 0.090 |
Why?
|
| Kidney Calculi | 1 | 2010 | 19 | 0.090 |
Why?
|
| Splenectomy | 1 | 2010 | 40 | 0.090 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2010 | 9 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2010 | 14 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2010 | 120 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 52 | 0.090 |
Why?
|
| Creatinine | 1 | 2010 | 243 | 0.090 |
Why?
|
| Anthropometry | 1 | 2009 | 64 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 955 | 0.080 |
Why?
|
| Infant | 5 | 2015 | 2891 | 0.080 |
Why?
|
| Incidence | 4 | 2015 | 1603 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2015 | 756 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2010 | 205 | 0.080 |
Why?
|
| Osteopontin | 1 | 2008 | 28 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 4655 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 1054 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.080 |
Why?
|
| Sepsis | 1 | 2010 | 233 | 0.070 |
Why?
|
| Remission Induction | 1 | 2007 | 111 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 126 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 104 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 3259 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2007 | 274 | 0.070 |
Why?
|
| Proteome | 1 | 2006 | 87 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 711 | 0.060 |
Why?
|
| Pain | 2 | 2017 | 472 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2010 | 1615 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 8 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 948 | 0.050 |
Why?
|
| DNA, Ribosomal | 1 | 2021 | 59 | 0.050 |
Why?
|
| Feces | 1 | 2021 | 88 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 150 | 0.050 |
Why?
|
| Algorithms | 2 | 2015 | 1196 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 3705 | 0.040 |
Why?
|
| Fatigue | 1 | 2017 | 132 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2007 | 223 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 209 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 39 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 58 | 0.030 |
Why?
|
| Time | 1 | 2015 | 57 | 0.030 |
Why?
|
| Specialization | 1 | 2015 | 66 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 117 | 0.030 |
Why?
|
| Rheumatology | 1 | 2015 | 46 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 392 | 0.030 |
Why?
|
| Essential Hypertension | 1 | 2014 | 2 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 2014 | 16 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 422 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 109 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 235 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2014 | 57 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 255 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 420 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 274 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2014 | 99 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 880 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 254 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2012 | 18 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 218 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 403 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 563 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2012 | 22 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 658 | 0.030 |
Why?
|
| Rituximab | 1 | 2012 | 61 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2012 | 22 | 0.030 |
Why?
|
| Global Health | 1 | 2012 | 136 | 0.020 |
Why?
|
| Pediatrics | 1 | 2015 | 341 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1465 | 0.020 |
Why?
|
| Depression | 1 | 2017 | 943 | 0.020 |
Why?
|
| Nephrolithiasis | 1 | 2010 | 9 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2012 | 183 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 581 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 114 | 0.020 |
Why?
|
| Acute Chest Syndrome | 1 | 2010 | 19 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 242 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 188 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2334 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2455 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2007 | 0.020 |
Why?
|
| Nephrosis, Lipoid | 1 | 2007 | 9 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2010 | 237 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2010 | 214 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 32 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 185 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 52 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2007 | 28 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 1056 | 0.020 |
Why?
|
| Podocytes | 1 | 2008 | 113 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 161 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 21403 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1745 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 742 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 947 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 4848 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1140 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1664 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 2279 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 1692 | 0.010 |
Why?
|
| South Carolina | 1 | 2010 | 2752 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 2083 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2673 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 2791 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2550 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 5300 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 2689 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 14862 | 0.010 |
Why?
|
| Stroke | 1 | 2010 | 2163 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 8474 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 21147 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 20881 | 0.010 |
Why?
|